Money Control Place
  • Politics
  • Business
  • Stocks
  • Investing
  • Politics
  • Business
  • Stocks
  • Investing

Money Control Place

Politics

Russia restricts abortion drug sales until 2030

by October 5, 2023
October 5, 2023
Russia restricts abortion drug sales until 2030

The Russian government is tightening restrictions on access to abortion-inducing drugs.

Russia’s Ministry of Health announced Tuesday new limits on abortion drug distribution and sales at pharmacies. 

Misoprostol and mifepristone are specifically being targeted with the restrictions. The two drugs are now limited by subject-quantitative registration, according to translations from the Moscow Times. 

The restrictions will go into effect on Sep. 1, 2024 and last for exactly six years.

Health Minister Mikhail Murashko first suggested adding the two abortion drugs to the registry in July, saying they pose both medical and ethical risks for Russian women. 

Russia is currently experiencing a cultural shift in its attitudes toward abortion. Previously rather liberal on the issue, the country’s leadership and conservative communities have seized the current climate to propagate anti-abortion regulations. 

The Russian Orthodox Church — which enjoys a historically significant relationship with the nation’s politics — is also vehemently opposed to abortion on the basis of Christian morals.

Under the new restrictions, individuals seeking the drug will need to obtain a prescription from a doctor before purchasing. 

Additionally, medical providers will require a special license to provide the abortion-inducing medication to patients. 

Providers will also have to track and report their distribution of the drugs.

Timothy Nerozzi is a writer for Fox News Digital. You can follow him on Twitter @timothynerozzi and can email him at timothy.nerozzi@fox.com

This post appeared first on FOX NEWS
0
FacebookTwitterGoogle +Pinterest
previous post
Biden says Dems, GOP ‘remain committed’ to bipartisan solutions following McCarthy ouster
next post
Steve Scalise, McCarthy’s longtime No. 2, announces bid for House speaker

Related Posts

Biden admin moves to unleash apex predator near...

September 30, 2023

New poll reveals which party is more enthusiastic...

April 30, 2024

Top GOP senator slams climate czar John Kerry’s...

July 19, 2023

New Mexico sheriff says she won’t enforce ‘unconstitutional’...

September 12, 2023

Trump to appear in federal court after special...

June 13, 2023

FBI tracks over 100 incidents of Chinese nationals...

September 5, 2023

Hur testifies Biden ‘willfully retained classified materials,’ but...

March 13, 2024

Maui emergency management admin resigns day after questioned...

August 18, 2023

PETA skewered for claiming that people eat animals...

June 20, 2023

Trump says Pelosi ‘probably a little bit smarter’...

March 3, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Breakouts, Momentum & Moving Averages: 10 Must-See Stock Charts Right Now

    • Week Ahead: NIFTY Stays In A Defined Range; Moving Past This Level Crucial For Resumption Of Upmove

    • Editor’s Picks: Gold Faces Bumpy Week on Trade Tensions, Platinum Stages Breakout

    • Run Your Stock Portfolio Like a Pro Sports Team

    • Leadership Rotation Could Confirm Corrective Phase

    • Breakouts, Momentum & Moving Averages: 10 Must-See Stock Charts Right Now

    Categories

    • Business (1,223)
    • Investing (2,504)
    • Politics (3,699)
    • Stocks (1,616)
    • Uncategorized (20)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: MoneyControlPlace.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 moneycontrolplace.com | All Rights Reserved